Meta-analysis: Angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction

Annals of Internal Medicine

Volumn 141, Issue 9, 2004, Pages 693-704

  Lee, Victor C ^a   Rhew, David C ^b   Dylan, Michelle ^b   Badamgarav, Enkhe ^b   Braunstein, Glenn D ^b   Weingarten, Scott R ^b  

^a Zynx Health   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; LISINOPRIL; LOSARTAN; PLACEBO; TELMISARTAN; VALSARTAN;

ACUTE HEART INFARCTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; HEART FAILURE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS;

EID: 7244227872     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-141-9-200411020-00011     Document Type: Review

References (51)

1. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996;334:1649-54. [PMID: 8628362]
2. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88:1602-9. [PMID: 8403307]
3. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, et al. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation. 1995;91:691-7. [PMID: 7828295]
4. Wong M, Staszevreky L, Latini R, Barlera S, Volpi A, Chiang YT, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40:970-5. [PMID: 12225725]
5. Schieffer B, Drexler H. Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases. Am J Cardiol. 2003;91:12H-18H. [PMID: 12818730]
6. Phillips MI, Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs. 2002;3:569-77. [PMID: 12090726]
7. Mann DL. Angiotensin II as an inflammatory mediator: evolving concepts in the role of the renin angiotensin system in the failing heart [Editorial]. Cardiovasc Drugs Ther. 2002;16:7-9. [PMID: 12085982]
8. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation. 2001;104:2996-3007. [PMID: 11739319]
9. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J Card Fail. 1999;5:357-82. [PMID: 10634677]
10. Joint Commission on Accreditation of Healthcare Organizations. Overview of the Heart Failure (HF) Core Measure Set. Oakbrook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations; 2002. Accessed at www.jcaho.org/pms/core+measures/hf_overview.htm on 31 August 2004.
11. Centers for Medicare & Medicaid Services. Hospital Quality Initiative Overview. Baltimore, MD: Centers for Medicare & Medicaid Services; 2004. Accessed at www.cms.hhs.gov/quality/hospital/overview.pdf on 31 August 2004.
12. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575-81. [PMID: 10821360]
13. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2002;39:463-70. [PMID: 11823085]
14. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-66. [PMID: 13678868]
15. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-6. [PMID: 13678870]
16. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-71. [PMID: 13678869]
17. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362: 777-81. [PMID: 13678871]
18. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752-60. [PMID: 12241832]
19. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906. [PMID: 14610160]
20. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA. 1992;268:240-8. [PMID: 1535110]
21. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248-54. [PMID: 1614465]
22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12. [PMID: 8721797]
23. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York: John Wiley & Sons; 1981.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. [PMID: 3802833]
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48. [PMID: 13655060]
26. Weber M. Clinical safety and tolerability of losartan. Clin Ther. 1997;19:604-16; discussion 603. [PMID: 9377606]
27. Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group. Am J Cardiol. 2000;85:187-92. [PMID: 10955375]
28. Murdoch DR, McDonagh TA, Farmer R, Morton JJ, McMurray JJ, Dargie HJ. ADEPT: Addition of the ATI receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J. 2001;141:800-7. [PMID: 11320369]
29. Matsumori A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail. 2003:5:669-77. [PMID: 14607207]
30. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995;26:438-45. [PMID: 7608448]
31. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-52. [PMID: 9074572]
32. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000:355:1582-7. [PMID: 10821361]
33. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation. 1999;99:990-2. [PMID: 10051289]
34. Willenheimer R, Helmers C, Pantev E, Rydberg E, Löfdahl P, Gordon A, et al. Safety and efficacy of valsartan versus enalapril in heart failure patients. Int J Cardiol. 2002;85:261-70. [PMID: 12208593]
35. Lang RM, Elkayam U, Yellen LG, Krauss D, McKelvie RS, Vaughan DE, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol. 1997;30:983-91. [PMID: 9316528]
36. Mazayev VP, Fomina IG, Kazakov EN, Sulimov VA, Zvereva TV, Lyusov VA, et al. Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol. 1998;65:239-46. [PMID: 9740480]
37. Mitrovic V, Willenbrock R, Miric M, Seferovic P, Spinar J, Dabrowski M, et al. Acute and 3-month treatment effects of candesartan cilexeti) on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. Am Heart J. 2003;145:E14. [PMID: 12660683]
38. Dunselman PH. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. Int J Cardiol. 2001;77:131-8; discussion 139-40. [PMID: 11182175]
39. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart iailure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056-64. [PMID: 10477530]
40. Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000;139:609-17. [PMID: 10740141]
41. Riegger GA, Bouzo H, Petr P, Münz J, Spacek R, Pethig H, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation. 1999;100:2224-30. [PMID: 10577995]
42. Tonkon M, Awan N, Niazi I, Hanley P, Baruch L, Wolf RA, et al. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group. Int J Clin Pract. 2000;54:11-4, 16-8. [PMID: 10750252]
43. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation. 1999;99:2658-64. [PMID: 10338459]
44. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75. [PMID: 11759645]
45. Barrowman NJ, Fang M, Sampson M, Moher D. Identifying null meta-analyses that are ripe for updating. BMC Med Res Methodol. 2003;3:13. [PMID: 12877755]
46. Joint Commission on Accreditation of Healthcare Organizations. Latest Core Measure News: 1/7/04 Statement Regarding ACEI/ARB. Accessed at www.jcaho.org/pms/core+measures/latest+core+measure+news.htm on 9 September 2004.
47. Executive Council Of The Heart Failure Society Of America. Implications of recent clinical trials for heart failure performance measures. J Card Fail. 2004;10:4-5. [PMID: 14966767]
48. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ. 1994;309:1351-5. [PMID: 7866085]
49. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancer. 1998;351:123-7. [PMID: 9439507]
50. Dasbach EJ, Rich MW, Segal R, Gerth WC, Carides GW, Cook JR, et al. The cosr-effectiveness of losartan versus captopril in patients with symptomatic heart failure. Cardiology. 1999;91:189-94. [PMID: 10516413]
51. Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am J Cardiol. 2003;91:28G-34G. [PMID: 12781906]